Class III Antiarrhythmic Agents for Mitochondrial DNA Instability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mitochondrial diseases, particularly those caused by mutations in the POLG gene, are limited to symptom management with no curative options, and existing therapies like vitamins and cofactors lack evidence for effectiveness.
Innovation Solution
Development of compounds, such as clofilium tosylate, dofetilide, and ibutilide, which are administered to treat or prevent diseases related to mitochondrial DNA instability by addressing the underlying genetic issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vitamins and cofactors are used to strengthen mitochondrial functions, then mitochondrial support is provided, but there is lack of evidence supporting their use
Solution Approach 1:
The patent changes the therapeutic parameter from using vitamins and cofactors to using class III antiarrhythmic agents (clofilium tosylate, dofetilide, ibutilide) which block potassium channels. This parameter change is based on the discovery that potassium channel blocking restores mitochondrial DNA stability and improves mitochondrial function in POLG-related diseases, providing a evidence-based alternative to the previously unproven vitamin therapy
2Reliability
If liver transplantation is performed in adults with AHS, then quality of life can be beneficial, but it is not recommended for children as it will have no effect on rapid progression of neurological damage
Solution Approach 1:
The patent develops a universal treatment approach using class III antiarrhythmic agents that can be applied to both children and adults with POLG-related mitochondrial diseases. Unlike liver transplantation which is age-limited, these compounds can prevent mitochondrial DNA depletion and neurological damage progression in pediatric patients while also benefiting adult patients, making the therapy universally applicable across all age groups
3Ease of operation
If current symptom management treatments are used, then disease progression is managed, but no curative treatment is available
Solution Approach 1:
The patent employs preliminary action by using class III antiarrhythmic agents to prevent mitochondrial DNA depletion and neurological damage before they occur in pediatric patients. This preventive approach addresses the underlying cause rather than just managing symptoms, potentially stopping disease progression at an early stage and providing a curative effect rather than merely palliative symptom management
Data Source
AI summary
Disclosed is a compound of formula (Ia) for the use thereof in the treatment or prevention of diseases relating to the instability of mitochondrial DNA.